A French health agency has launched a temporary scientific committee to assess how to create a medical cannabis market in France.
The nation legalized cannabis-based medicines in 2013, but no product is legally available because the market has not been developed.
The French National Agency for the Safety of Medicines and Health Products (ANSM) has tasked the committee with:
- Evaluating scientific data related to medical cannabis.
- Assessing the experiences of other countries that have implemented such a program.
- Considering patient experiences and feedback in other markets.
The committee will assess the feasibility of creating an MMJ market, which medical conditions it should be allowed for and how such a market would be accessed.
The committee, whose members are expected to be chosen soon, is expected to provide its first conclusions by the end of the year.